MESO Q4 2024 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-41.2% YoY

Gross Profit

-$10M-762.3% margin

Operating Income

-$22M-1750.7% margin

Net Income

-$28M-2204.3% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

-$86,000

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$669M

Total Liabilities

$189M

Stockholders' Equity

$480M

Cash & Equivalents

$63M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$2M	-41.2%
Gross Profit	-$10M	-$13M	+27.9%
Operating Income	-$22M	-$19M	-15.4%
Net Income	-$28M	-$22M	-26.4%